Evidence map›Paper›PMID 19819324›Full record

ArticleExperimental gerontology2010

Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.

Katarzyna A Gustaw-Rothenberg, Sandra L Siedlak, David J Bonda, Alan Lerner, Massimo Tabaton, George Perry, Mark A Smith

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental gerontology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  4. Article
  5. A Novel Serum-Based Diagnosis of Alzheimer's Disease Using an Advanced Phage-Based Biochip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. The future of blood-based biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Katarzyna A Gustaw-RothenbergDepartment of Neurology, University Hospitals-Case Medical Center and University Memory and Cognition Center, Cleveland, OH 44106, USA. katarzyna.gustaw-rothenberg@case.edu
Sandra L Siedlak
David J Bonda
Alan Lerner
Massimo Tabaton
George Perry
Mark A Smith
Case Western Reserve University · USUniversity Hospitals Case Medical Center · USUniversity of Genoa · IT

Funding

Amyloid-beta: The Alternate HypothesisR01AG026151 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI SMITH, MARK A · 2005 to 2007
$741k
NIA NIH HHS AG026151NIA NIH HHS R01 AG026151
6 · The paper itself

Abstract

With an ever growing population of aged individuals who are at risk of developing Alzheimer disease (AD), there is an urgent need for a sensitive, specific, and preferably non-invasive diagnostic standard of disease progression. Mainstream thinking suggests that early intervention is key to maximizing the opportunity for a successful treatment regimen in AD and, as such, an early and accurate means of diagnosis is essential. In this study, we applied a recently described antibody-antigen dissociation technique to samples obtained as part of a population-based analysis of the prevalence of AD. Stratified sampling and random selection strategies were combined to obtain a representative population for screening of individuals older than 55 years. Serum antibodies to amyloid-beta (Abeta)(1-42) were measured before and after antigen dissociation. The difference between the two measurements was indicated as the dissociation delta (Delta). Our analyses showed that the levels of dissociated antibody in AD patients were always significantly different from controls and that levels of Abeta antibody after dissociation, but not those of non-dissociated antibody, correlated negatively (p<0.05) with both duration of the disease and age in the AD patients. Moreover, the change in concentration of Abeta antibody from pre- to post-dissociation (i.e., the dissociation Delta) directly reflected the progression of AD in terms of both time since diagnosis and age of the patients, with a lower dissociation Delta indicating a more advanced stage of AD. Ultimately, these data suggest that dissociated Abeta antibody levels are of significant diagnostic value at the onset of the neurodegenerative process and, thereafter, may be a useful biomarker for disease progression.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overAmyloid beta-PeptidesAntigen-Antibody ComplexAutoantibodiesBiomarkersDisease ProgressionEarly DiagnosisEnzyme-Linked Immunosorbent AssayHumansMiddle AgedRisk FactorsSensitivity and SpecificitySeroepidemiologic StudiesAmyloid beta-PeptidesAntigen-Antibody ComplexAutoantibodiesBiomarkers

Identifiers

PMID19819324
PMCPMC2815174
OpenAlexW2066920898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.